GH
Price
$114.04
Change
+$3.56 (+3.22%)
Updated
Jan 30 closing price
Capitalization
14.81B
18 days until earnings call
Intraday BUY SELL Signals
MYGN
Price
$5.62
Change
+$0.08 (+1.44%)
Updated
Jan 30 closing price
Capitalization
523.86M
30 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

GH vs MYGN

Header iconGH vs MYGN Comparison
Open Charts GH vs MYGNBanner chart's image
Guardant Health
Price$114.04
Change+$3.56 (+3.22%)
Volume$2.02M
Capitalization14.81B
Myriad Genetics
Price$5.62
Change+$0.08 (+1.44%)
Volume$916.65K
Capitalization523.86M
GH vs MYGN Comparison Chart in %
View a ticker or compare two or three
VS
GH vs. MYGN commentary
Feb 01, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GH is a Hold and MYGN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 01, 2026
Stock price -- (GH: $114.04 vs. MYGN: $5.62)
Brand notoriety: GH: Notable vs. MYGN: Not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: GH: 108% vs. MYGN: 97%
Market capitalization -- GH: $14.81B vs. MYGN: $523.86M
GH [@Medical Specialties] is valued at $14.81B. MYGN’s [@Medical Specialties] market capitalization is $523.86M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $12.4B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GH’s FA Score shows that 0 FA rating(s) are green whileMYGN’s FA Score has 1 green FA rating(s).

  • GH’s FA Score: 0 green, 5 red.
  • MYGN’s FA Score: 1 green, 4 red.
According to our system of comparison, MYGN is a better buy in the long-term than GH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GH’s TA Score shows that 3 TA indicator(s) are bullish while MYGN’s TA Score has 4 bullish TA indicator(s).

  • GH’s TA Score: 3 bullish, 5 bearish.
  • MYGN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, MYGN is a better buy in the short-term than GH.

Price Growth

GH (@Medical Specialties) experienced а -0.62% price change this week, while MYGN (@Medical Specialties) price change was -4.26% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -3.57%. For the same industry, the average monthly price growth was +3.48%, and the average quarterly price growth was +29.64%.

Reported Earning Dates

GH is expected to report earnings on Feb 19, 2026.

MYGN is expected to report earnings on Mar 03, 2026.

Industries' Descriptions

@Medical Specialties (-3.57% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GH($14.8B) has a higher market cap than MYGN($524M). GH YTD gains are higher at: 11.651 vs. MYGN (-8.618). GH (-354.11M) and MYGN (-362.6M) have comparable annual earnings (EBITDA) . GH has more cash in the bank: 580M vs. MYGN (145M). MYGN has less debt than GH: MYGN (212M) vs GH (1.33B). GH has higher revenues than MYGN: GH (903M) vs MYGN (825M).
GHMYGNGH / MYGN
Capitalization14.8B524M2,824%
EBITDA-354.11M-362.6M98%
Gain YTD11.651-8.618-135%
P/E RatioN/AN/A-
Revenue903M825M109%
Total Cash580M145M400%
Total Debt1.33B212M625%
FUNDAMENTALS RATINGS
GH vs MYGN: Fundamental Ratings
GH
MYGN
OUTLOOK RATING
1..100
3356
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
99
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
3663
P/E GROWTH RATING
1..100
1001
SEASONALITY SCORE
1..100
90n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GH's Valuation (78) in the Medical Or Nursing Services industry is in the same range as MYGN (99) in the Biotechnology industry. This means that GH’s stock grew similarly to MYGN’s over the last 12 months.

GH's Profit vs Risk Rating (100) in the Medical Or Nursing Services industry is in the same range as MYGN (100) in the Biotechnology industry. This means that GH’s stock grew similarly to MYGN’s over the last 12 months.

MYGN's SMR Rating (98) in the Biotechnology industry is in the same range as GH (100) in the Medical Or Nursing Services industry. This means that MYGN’s stock grew similarly to GH’s over the last 12 months.

GH's Price Growth Rating (36) in the Medical Or Nursing Services industry is in the same range as MYGN (63) in the Biotechnology industry. This means that GH’s stock grew similarly to MYGN’s over the last 12 months.

MYGN's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for GH (100) in the Medical Or Nursing Services industry. This means that MYGN’s stock grew significantly faster than GH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GHMYGN
RSI
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 3 days ago
80%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
82%
Bullish Trend 3 days ago
70%
Momentum
ODDS (%)
Bullish Trend 3 days ago
84%
Bearish Trend 3 days ago
88%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
80%
Bearish Trend 3 days ago
83%
Advances
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 11 days ago
72%
Declines
ODDS (%)
Bearish Trend 5 days ago
84%
Bearish Trend 4 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
74%
Bullish Trend 3 days ago
74%
Aroon
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
GH
Daily Signal:
Gain/Loss:
MYGN
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AMIDX17.51N/A
N/A
Amana Developing World Institutional
FOSCX29.44-0.03
-0.10%
Tributary Small Company Instl
LHCFX22.53-0.04
-0.18%
Lord Abbett Health Care F
GUXPX5.61-0.01
-0.18%
Gabelli Utilities C
FGRTX32.21-0.10
-0.31%
Fidelity Mega Cap Stock

GH and

Correlation & Price change

A.I.dvisor indicates that over the last year, GH has been loosely correlated with NTRA. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if GH jumps, then NTRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GH
1D Price
Change %
GH100%
+3.22%
NTRA - GH
52%
Loosely correlated
-0.15%
RGEN - GH
42%
Loosely correlated
-4.48%
GKOS - GH
40%
Loosely correlated
+0.26%
ITGR - GH
40%
Loosely correlated
+0.45%
MASI - GH
40%
Loosely correlated
+0.79%
More

MYGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, MYGN has been loosely correlated with WAT. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if MYGN jumps, then WAT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MYGN
1D Price
Change %
MYGN100%
+1.44%
WAT - MYGN
39%
Loosely correlated
-1.19%
ATEC - MYGN
34%
Loosely correlated
-0.13%
AORT - MYGN
31%
Poorly correlated
+0.87%
MASI - MYGN
30%
Poorly correlated
+0.79%
GH - MYGN
29%
Poorly correlated
+3.22%
More